A phase III, randomized, double-blind, multi-center, parallel-group, placebo-controlled, dose optimization study, designed to evaluate the safety and efficacy of methylphenidate transdermal system (MTS) vs. Concerta in pediatric patients aged 6-12 with attention-deficit/hyperactivity disorder (ADHD)

Trial Profile

A phase III, randomized, double-blind, multi-center, parallel-group, placebo-controlled, dose optimization study, designed to evaluate the safety and efficacy of methylphenidate transdermal system (MTS) vs. Concerta in pediatric patients aged 6-12 with attention-deficit/hyperactivity disorder (ADHD)

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2015

At a glance

  • Drugs Methylphenidate (Primary) ; Methylphenidate
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shire Pharmaceutical Development
  • Most Recent Events

    • 01 Jan 2008 Results have been published.
    • 27 Apr 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top